



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,111	02/15/2002	C. Gordon Todderud	D0031 NP	1564
7590	02/24/2005			EXAMINER
BRISTOL-MYERS SQUIBB COMPANY			ZARA, JANE J	
P.O. Box 4000			ART UNIT	PAPER NUMBER
Route 206 and Provinceline Road			1635	
Princeton, NJ 08543				

DATE MAILED: 02/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.	10/077,111	Applicant(s)	TODDERUD ET AL.
Examiner	Jane Zara	Art Unit	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

**A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM  
THE MAILING DATE OF THIS COMMUNICATION.**

- Extensions of time may be available under the provisions of 37 CFR 1.136(e). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply is specified above, the shortened statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the shortened statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1)  Responsive to communication(s) filed on 09 June 2004.  
2a)  This action is FINAL. 2b)  This action is non-final.  
3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4)  Claim(s) 5,6,9-14,18,19 and 21-39 is/are pending in the application.  
4a) Of the above claim(s) 5,6,9-14,18 and 19 is/are withdrawn from consideration.  
5)  Claim(s) \_\_\_\_\_ is/are allowed.  
6)  Claim(s) 21-39 is/are rejected.  
7)  Claim(s) \_\_\_\_\_ is/are objected to.  
8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9)  The specification is objected to by the Examiner.  
10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892)  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 10-15-02 and 8-29-03 4)  Interview Summary (PTO-413)  
Paper No(s)/Mail Date, \_\_\_\_\_.  
5)  Notice of Informal Patent Application (PTO-152)  
6)  Other: Sequence alignments.

**DETAILED ACTION**

This Office action is in response to the communication filed 6-9-04.

Claims 5, 6, 9-14, 18, 19 and 21-39 are pending in the instant application.

***Election/Restrictions***

Claims 5, 6, 9-14, 18, 19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected elections, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 6-9-04.

Applicant's election without traverse of Group I, claims 1-4, 7, 8, 15-17 and 20, now replaced by claims 21-39, and SEQ ID NO: 12 in the reply filed on 6-9-04 is acknowledged.

***Information Disclosure Statement***

Reference "AO" provided in the IDS filed 10-15-02 has not been considered because it was not in English and there is no translation from Chinese.

***Specification Objection and Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 21-35, 37-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 21, line 6, and claim 37, line 8, the term "corresponding to" is vague and unclear. Appropriate clarification is requested.

This application does not comply with the rules for the deposit of biological material as set forth below in the Suggestion for Deposit of Biological Material. For ATCC deposits, please be sure to use the current address in Virginia, rather than the former address in Maryland.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to and claims 21-36 are rejected under 35 USC § 112, first paragraph as failing to provide an enabling disclosure for the claimed invention.

The application discloses ATCC Accession No. PTA-3161 (see claim 21, line 11) that is encompassed by the definitions for **biological material** set forth in 37 C.F.R. § 1.801. Because it is apparent that this biological material is essential for practicing the claimed invention, it must be obtainable by a reproducible method set forth in the specification or otherwise be known and readily available to the public as detailed in 37 C.F.R. §§ 1.801 through 1.809.

It is unclear whether this biological material is known and readily available to the public or that the written instructions are sufficient to reproducibly construct this

biological material from starting materials known and readily available to the public. Accordingly, availability of such biological material is deemed necessary to satisfy the enablement provisions of 35 U.S.C. § 112. If this biological material is not obtainable or available, the requirements of 35 U.S.C. § 112 may be satisfied by a deposit of the biological material. In order for a deposit to meet all criteria set forth in 37 C.F.R. §§ 1.801-1.809, applicants or assignee must provide assurance of compliance with provisions of 37 C.F.R. §§ 1.801-1.809, in the form of a declaration or applicant's representative must provide a statement. The content of such a declaration or statement is suggested by the enclosed attachment. Because such deposit will not have been made prior to the effective filing date of the instant application, applicant is required to submit a verified statement from a person in a position to corroborate the fact, which states that the biological material which has been deposited is the biological material specifically identified in the application as filed (37 C.F.R. § 1.804). Such a statement need not be verified if the person is an agent or attorney registered to practice before the Office. Applicant is also reminded that the specification must contain reference to the deposit, including deposit (accession) number, date of deposit, name and address of the depository, and the complete taxonomic description.

#### **SUGGESTION FOR DEPOSIT OF BIOLOGICAL MATERIAL**

A declaration by applicant or assignee, or a statement by applicant's agent identifying a deposit of biological material and averring the following may be sufficient to overcome an objection or rejection based on a lack of availability of biological material. Such a declaration:

1. Identifies declarant.
2. States that a deposit of the material has been made in a depository affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. The depository is to be identified by name and address. (See 37 C.F.R. § 1.803).
3. States that the deposited material has been accorded a specific (recited) accession number.
4. States that all restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of the patent. (See 37 C.F.R. § 1.808(a)(2)).
5. States that the material has been deposited under conditions that assure that access to the material will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C. § 122. (See 37 C.F.R. § 1.808(a)(1)).
6. States that the deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited microorganism, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer. See 37 C.F.R. § 1.806.
7. That he/she declares further that all statements made therein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the instant patent application or any patent issuing thereon.

Alternatively, it may be averred that deposited material has been accepted for deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (e.g., see 961 OG 21, 1977) and

that all restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent.

Additionally, the deposit must be referred to in the body of the specification and be identified by deposit (accession) number, date of deposit, name and address of the depository, and the complete taxonomic description.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 21-39 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to isolated polynucleotides and methods comprising a nucleotide sequence at least 82% identical to SEQ ID NO: 12, or encoding an amino acid sequence of a cell signaling polypeptide involved in cell signaling cascade and having at least 82% sequence identity with SEQ ID NO: 13, or encoding a polypeptide or fragment thereof sharing at least 68.2% sequence identity with SEQ IDN No: 12, or detecting a polynucleotide encoding a ubiquitin conjugating enzyme or fragment thereof. The specification and claims do not adequately describe the elements essential to the genera comprising these sequence variants, nor do they describe the genus comprising a cell signaling polypeptide

involved in a cell signaling cascade or ubiquitin conjugating enzyme or fragment thereof. The disclosure does not clarify the common attributes encompassed by these very broad genera. The scope of the claims includes numerous structural variants and the genera are highly variant because a significant number of structural differences between members of a given genus is permitted. Concise structural features that distinguish structures within the various genera are missing from the disclosure and the claims. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the various genera claimed. Thus, Applicant was not in possession of the claimed genera.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 21-27, 29-39 are rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al.

Tang et al (USPN 6,569,662) teach methods and compositions comprising polynucleotides comprising or consisting of a nucleotide sequence at least 82%

identical to SEQ ID NO: 12, or encoding an amino acid sequence of a cell signaling polypeptide involved in cell signaling cascade and having at least 82% sequence identity with SEQ ID NO: 13, or their complementary sequence, or encoding a polypeptide or fragment thereof sharing at least 68.2% sequence identity with SEQ IDN No; 12, and which compositions further comprise an appropriate host cell comprising an appropriate expression vector comprising the polynucleotides above, and which methods comprise producing a recombinant polypeptide comprising expressing these polynucleotides, and which methods also comprise detecting the hybridization complex of the polynucleotides (see SEQ ID NO: 768 of USPN 6,569,662 and accompanying sequence alignment data attached to the Office action; see also col. 9-11, 12-16, and 19-23).

Claims 21, 30 and 37 are rejected under 35 U.S.C. 102(b) as being anticipated by Birin et al.

Birin et al teach a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide of SEQ ID NO: 13 or fragment thereof sharing at least 68.2% sequence identity with SEQ IDN No: 12 (see Accession No. AC006501 of Birin et al and accompanying sequence alignment data, attached to Office action).

### ***Conclusion***

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94

(December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is **703-872-9306**. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (571) 272-0760. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JZ  
2-20-05

83 7<1600





## REFERENCE

1

AUTHORS Yue, H., Tang, Y. T., Bandaru, O., Hillman, J. L., Lal, P., Au-Young, J., Reddy, R., Yang, J., Baugh, M. R., Liu, D. K., Aizawa, Y., and Patterson, C.

TITLE Pp-Brn1ngin protein associated factors

JOURNAL *Infect Dis*

REPORT NUMBER 10211053970-A-130 15-JAN-2001;

INSTITUTE Genzyme Inc. (US)

## FEATURES

source

1. *1231 Qualifiers*

/organism="Homo sapiens"

/mol\_type="nucleic acid"

/db\_xref="taxon:666"

/note="Incyte ID No: 4546403CB1"

## ALIGNMENT

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

/organism="Homo sapiens"

/mol\_type="nucleic acid"

/db\_xref="taxon:666"

/note="Incyte ID No: 4546403CB1"

## ORIGIN

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

/organism="Homo sapiens"

/mol\_type="nucleic acid"

/db\_xref="taxon:666"

/note="Incyte ID No: 4546403CB1"

## REF-1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

/organism="Homo sapiens"

/mol\_type="nucleic acid"

/db\_xref="taxon:666"

/note="Incyte ID No: 4546403CB1"

## REF-2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

/organism="Homo sapiens"

/mol\_type="nucleic acid"

/db\_xref="taxon:666"

/note="IncYTE ID No: 4546403CB1"

## REF-3

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44



